Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FTC/TAF/BIC monotherapy in HIV-infected patients with unsuppressed virus and drug-resistant mutations
ChiCTR2200065826Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Nanjing
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS), sponsored by The Second Hospital of Nanjing. Primary endpoints: CD4 count and HIV viral load. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)acquired immunodeficiency syndrome (AIDS)
Beyond the preview
Go deeper on ChiCTR2200065826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065826.